Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Impersonating a S.E.C. employee is a Federal criminal offence, BGMO lawyers and the S.E.C. are well aware of this con artist and his co-conspirators charades.
Anyone else who would like to report this con artist Terry Thompson to the S.E.C. for violations of the Federal criminal laws, follow the link below
Also Global Arena was not an Incorporated company in the year 2000 to 2005, this con artist should be reported to the S.E.C. by all shareholders.
http://www.linkedin.com/profile/view?id=231384327&authType=name&authToken=Aole&goback=%2Ewvp_*1_*1_*1&trk=wvmx_p
http://www.sec.gov/news/press/2009/2009-39.htm
http://law.onecle.com/michigan/750-michigan-penal-code/mcl-750-217c.html
BGMO is as real as a heart attack
Just Keeping Them Honest
According to the recent 8-K S.E.C. Edgar filings, BGMO will control approximately 72% of VSTA. WOW !!!!
Great news for BGMO shareholders and only the beginning of the acquisition trail for BGMO !!!!!
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp. (OTC: BGMO), a global diversified investment holding company.
Under the terms of the agreement, Bergamo's European subsidiary will invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen Common Stock at a price of $0.50 per share. The Company's self-placed strategic financing does not include warrants or any investment banking fees. The transaction is scheduled to close on or before April 30, 2013. At closing, the shares issued in connection with the strategic financing will represent a majority of the issued and outstanding shares of VistaGen's Common Stock.
VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe™ 3D and LiverSafe™ 3D bioassay systems and modern medicinal chemistry, the Company is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. In collaboration with co-founder and renowned stem cell research scientist, Dr. Gordon Keller, as well as long-term strategic partner, the University Health Network in Toronto, and several other leading academic and corporate collaborators, VistaGen also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube™ platform.
"Since our inception nearly 15 years ago, we have carefully deployed more than $53 million, including over $15 million from grant awards and collaboration revenue, to successfully develop innovative stem cell technology and bioassay systems capable of bringing clinically relevant human heart and liver biology to the front end of the drug development process," stated Shawn K. Singh, VistaGen's Chief Executive Officer. "Upon the closing of this transformative financing, our strong long-term financial position will enhance substantially our ability to drive our core programs to valuable commercial outcomes."
Impersonating a S.E.C. employee is a Federal criminal offence, BGMO lawyers and the S.E.C. are well aware of this con artist and his co-conspirators charades.
Anyone else who would like to report this con artist Terry Thompson to the S.E.C. for violations of the Federal criminal laws, follow the link below
Also Global Arena was not an Incorporated company in the year 2000 to 2005, this con artist should be reported to the S.E.C. by all shareholders.
http://www.linkedin.com/profile/view?id=231384327&authType=name&authToken=Aole&goback=%2Ewvp_*1_*1_*1&trk=wvmx_p
http://www.sec.gov/news/press/2009/2009-39.htm
http://law.onecle.com/michigan/750-michigan-penal-code/mcl-750-217c.html
BGMO is as real as a heart attack
Just Keeping Them Honest
Impersonating a S.E.C. employee is a Federal criminal offence, BGMO lawyers and the S.E.C. are well aware of this con artist and his co-conspirators charades.
Anyone else who would like to report this con artist Terry Thompson to the S.E.C. for violations of the Federal criminal laws, follow the link below
Also Global Arena was not an Incorporated company in the year 2000 to 2005, this con artist should be reported to the S.E.C. by all shareholders.
http://www.linkedin.com/profile/view?id=231384327&authType=name&authToken=Aole&goback=%2Ewvp_*1_*1_*1&trk=wvmx_p
http://www.sec.gov/news/press/2009/2009-39.htm
http://law.onecle.com/michigan/750-michigan-penal-code/mcl-750-217c.html
BGMO is as real as a heart attack
Just Keeping Them Honest
YOU'RE WRONG AGAIN, HEARD IT ALL BEFORE ( YAWN )
HSBC USD 1,000,000,000,00 ( DONE DEAL )
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
YOUR OPINIONS ARE WRONG AGAIN
So far the shareholders have only heard opinions please provide links to back up your opinion that this time is no different.
There is plenty of evidence that this is very different ( including a Bank Statement filed with OTC markets, and a CPA letter verifying the Bank Statement )
How BGMO Secured USD 1,000,000,000.00 CASH FUNDING
1. HSBC Bank Statement posted on OTC MARKETS Filings on Jan 29th, 2013.
2. HSBC BANK A/C Holder’s Name.
3. HSBC BANK A/C Number.
4. HSBC BANK A/C Authorized Signatory.
5. HSBC BANK A/C Bank Officer Name and Title
6. HSBC BANK A/C Bank Officer Bank E-Mail Address.
7. HSBC BANK A/C 2nd BANK OFFICER Title and E-Mail Address
8. HSBC BANK A/C Main Branch Phone Number.
CPA ADMITS IN THE 1ST Line of his Letter JAN 25TH, 2013).
“QUOTE BY CPA” I am writing this letter at your request to (“VARIFY”) certain
Information CPA received during his meeting on Jan 23rd, 2013 with the management of Bergamo Acquisition Corp.
“QUOTE BY CPA” This letter can serve as a summary of the documents only as
“ADDITIONAL” information included in the originals agreements.
“QUOTE BY CPA” BGMO AFFILIATE WAS GRANTED USD 1,000,000,000.00
National Wealth Ltd.
“QUOTE BY CPA” NATIONAL WEALTH LTD was granted USD 1,000,000,000.00
On Jan 18, 2013. For a period of three years.
“QUOTE BY CPA” The Documents reference CASH deposit with HSBC totaling
USD 1,000,000,000.00.
“QUOTE BY CPA” Pursuant to the documents through a bond power, Deed of Assignment,
Bond Power hereby referred to as “Grantee” is National Wealth Ltd, Affiliate of Bergamo Acquisition Corp.
a) CPA Letter Dated Sep 19th, 2012
b) CPA Letter Dated Jan 25th, 2013
c) OTCMARKETS Filings Section, Review Bank Statement
d) OTCMARKETS Filings Section, Review powers authorized to the
“Grantee” which is National Wealth Ltd affiliate of Bergamo Acquisition Corp
e) Bank Statement is posted showing CASH deposit of USD 1,000,000,000.00.
f) Press Release Issued on Jan 10th, 2013 and Press Release Dated Jan 31st, 2013.
HSBC USD 1,000,000,000,00 ( DONE DEAL )
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
VistaGen Appoints Industry Veteran Shawn Singh as Chief Executive Officer
Seasoned Biotech Executive to Lead VistaGen’s Stem Cell-based Clinical Trials in a Test TubeTM Platform Focused on Transforming the Way New Drugs Are Discovered and Developed
SOUTH SAN FRANCISCO, CA (August 20, 2009) — VistaGen Therapeutics has named Shawn K. Singh as Chief Executive Officer. Mr. Singh was Managing Principal of Cato BioVentures, one of VistaGen’s largest institutional investors, and the Company’s President (part-time). Mr. Singh also served as Chief Business Officer, President, CEO or Chairman of five different biopharmaceutical companies, as well as CBO and General Counsel of Cato Research Ltd., a global contract research and development organization. Ralph Snodgrass, PhD, VistaGen’s founder and former CEO, will continue to serve as President and Chief Scientific Officer. Both Dr. Snodgrass and Mr. Singh are members of VistaGen’s Board of Directors.
VistaGen is one of the leading companies worldwide focused on using the power of stem cell technologies to transform the way new medicines are discovered and developed. The Company’s internal programs are focused on discovery and development of next generation drugs to treat Alzheimer’s, cancer and diabetes.
“VistaGen is a dynamic company marked by visionary technology, a rich history of innovation and a remarkable ability to navigate through intense economic and political headwinds without veering off course,” said Shawn Singh. “We believe better human response information can lead to better medicine. By using our Clinical Trials in a Test TubeTM platform to focus on how new drugs work in the body and how they interact with people with specific genetic differences, we are confident that our founding vision can become a medical reality.” He added, “I am honored to have the opportunity to lead a team so passionately focused on commercializing science that will make a difference.”
“I have worked with Shawn for eight years, and I strongly support both his appointment as CEO and my new role as President and Chief Scientific Officer,” said Dr. Ralph Snodgrass. “Together, these changes significantly broaden and strengthen our management team, enabling us to accomplish more than ever before, both commercially and scientifically, and I look forward to this new phase in our corporate development.”
“VistaGen is moving rapidly on many business fronts,” said Jon Saxe, VistaGen’s Chairman. “We are fortunate to have available someone of Shawn’s leadership skills and extensive experience with a wide range of life science companies and technologies to lead VistaGen’s efforts to realize the full commercial potential of its stem cell technologies. At the same time, the continued service of our founder, Ralph Snodgrass, as President and CSO is invaluable. Shawn’s availability as CEO on a full- time basis will enable Ralph to devote more time to strategic vision and scientific development of the platform, including collaborations with commercial partners and our esteemed network of academic stem cell research centers.”
VistaGen’s stem cell-based Clinical Trials in a Test TubeTM platform is focused on creating in human cells a comprehensive picture of the intricate details of human biology and human disease in ways that conventional animal models and non-human cell culture systems can only approximate. This enables drug developers to test for drug toxicity and efficacy in the lab quickly and efficiently, before costly human clinical trials.
Mr. Singh began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster. He later served as Chief Business Officer of SciClone Pharmaceuticals (NASDAQ: SCLN), Chief Business Officer and General Counsel of Cato Research Ltd., a global contract research and development organization, Chief Operating Officer and Managing Principal of Cato BioVentures, the venture capital affiliate of Cato Research Ltd, President of Echo Therapeutics (OTCBB: ECTE), Chairman of the Board and President of Durham Pharmaceuticals, President of Artemis Neuroscience, and Chief Executive Officer of Hemodynamic Therapeutics.
Mr. Singh received a B.A. from the University of California, Berkeley, and a J.D. from The University of Maryland School of Law. He currently serves on the Board of Directors of Echo Therapeutics and Hemodynamic Therapeutics and as a strategic advisor to Cato BioVentures and several other private biopharmaceutical companies.
VistaGen Therapeutics, Inc. is a South San Francisco-based biotechnology company that focuses on providing clinically relevant, commercially scalable, human stem cell biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. VistaGen’s Clinical Trials in a Test TubeTM platform is designed to generate predictive information that results in reduced probability of clinical trial drug failures, especially failures associated with heart and liver toxicity. VistaGen expects its new-generation stem cell-based human systems biology platform to enhance dramatically the pharmaceutical industry’s ability to deliver innovative drugs for some of the world’s most challenging diseases and conditions. For more information, visit: www.vistagen.com
?Media Contact
Christine Thomas
Russell Communications Group
(310) 922-5897
christinethomas@ruscom.com
And here is the same con man impersonating a Canadian citizen, check out " People Also Viewed "
Terry Thompson is a joke with zero credibility, and everything this con man says should be taken with the proverbial grain of salt.
Time to report this impersonating con man to the S.E.C. and the FBI
Just Keeping Them Honest
http://www.linkedin.com/profile/view?id=181605021&authType=name&authToken=rIqF&invAcpt=64749603_I340008272_60&goback=%2Epiv_I407609638*46
http://www.sec.gov/answers/impersonators.htm
According to the recent 8-K S.E.C. Edgar filings, BGMO will control approximately 72% of VSTA.
Great news for BGMO shareholders and only the beginning of the acquisition trail for BGMO !!!!!
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp. (OTC: BGMO), a global diversified investment holding company.
Under the terms of the agreement, Bergamo's European subsidiary will invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen Common Stock at a price of $0.50 per share. The Company's self-placed strategic financing does not include warrants or any investment banking fees. The transaction is scheduled to close on or before April 30, 2013. At closing, the shares issued in connection with the strategic financing will represent a majority of the issued and outstanding shares of VistaGen's Common Stock.
VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe™ 3D and LiverSafe™ 3D bioassay systems and modern medicinal chemistry, the Company is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. In collaboration with co-founder and renowned stem cell research scientist, Dr. Gordon Keller, as well as long-term strategic partner, the University Health Network in Toronto, and several other leading academic and corporate collaborators, VistaGen also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube™ platform.
"Since our inception nearly 15 years ago, we have carefully deployed more than $53 million, including over $15 million from grant awards and collaboration revenue, to successfully develop innovative stem cell technology and bioassay systems capable of bringing clinically relevant human heart and liver biology to the front end of the drug development process," stated Shawn K. Singh, VistaGen's Chief Executive Officer. "Upon the closing of this transformative financing, our strong long-term financial position will enhance substantially our ability to drive our core programs to valuable commercial outcomes."
If the shoe fits wear it !!!!!
Old news same old smell ( Shannon newby )
When will Shannon Newby move out of motel 6 ?
Never he is a low life loser
Shannon Newby just hangs around like a bad smell
HEHEHEHEHE
What would motivate someone to create a fake ID? There is only one Terry Thompson with a past business association with BGMO. He is a Con Man impersonating a S.E.C. employee and violating Federal criminal laws.
The Con Man and S.E.C. impersonator also said he was an employee of Global Arena, when it was not even incorporated yet. Did you not post that global Arena may be a target acquisition of BGMO ?
Impersonating a S.E.C. employee is a Federal criminal offence, BGMO lawyers and the S.E.C. are well aware of this con artist and his co-conspirators charades.
Anyone else who would like to report this con artist Terry Thompson to the S.E.C. or the FBI for violations of the Federal criminal laws, follow the link below
http://www.linkedin.com/profile/view?id=231384327&authType=name&authToken=Aole&goback=%2Ewvp_*1_*1_*1&trk=wvmx_p
http://www.sec.gov/news/press/2009/2009-39.htm
http://law.onecle.com/michigan/750-michigan-penal-code/mcl-750-217c.html
http://www.sec.gov/answers/impersonators.htm
BGMO is as real as a heart attack
Just Keeping Them Honest
What would motivate someone to create a fake ID? There is only one Terry Thompson with a past business association with BGMO. He is a Con Man impersonating a S.E.C. employee and violating Federal criminal laws.
The Con Man and S.E.C. impersonator also said he was an employee of Global Arena, when it was not even incorporated yet. Did you not post that global Arena may be a target acquisition of BGMO ?
Impersonating a S.E.C. employee is a Federal criminal offence, BGMO lawyers and the S.E.C. are well aware of this con artist and his co-conspirators charades.
Anyone else who would like to report this con artist Terry Thompson to the S.E.C. for violations of the Federal criminal laws, follow the link below
http://www.linkedin.com/profile/view?id=231384327&authType=name&authToken=Aole&goback=%2Ewvp_*1_*1_*1&trk=wvmx_p
http://www.sec.gov/news/press/2009/2009-39.htm
http://law.onecle.com/michigan/750-michigan-penal-code/mcl-750-217c.html
BGMO is as real as a heart attack
Just Keeping Them Honest
VistaGen Appoints Industry Veteran Shawn Singh as Chief Executive Officer
Seasoned Biotech Executive to Lead VistaGen’s Stem Cell-based Clinical Trials in a Test TubeTM Platform Focused on Transforming the Way New Drugs Are Discovered and Developed
SOUTH SAN FRANCISCO, CA (August 20, 2009) — VistaGen Therapeutics has named Shawn K. Singh as Chief Executive Officer. Mr. Singh was Managing Principal of Cato BioVentures, one of VistaGen’s largest institutional investors, and the Company’s President (part-time). Mr. Singh also served as Chief Business Officer, President, CEO or Chairman of five different biopharmaceutical companies, as well as CBO and General Counsel of Cato Research Ltd., a global contract research and development organization. Ralph Snodgrass, PhD, VistaGen’s founder and former CEO, will continue to serve as President and Chief Scientific Officer. Both Dr. Snodgrass and Mr. Singh are members of VistaGen’s Board of Directors.
VistaGen is one of the leading companies worldwide focused on using the power of stem cell technologies to transform the way new medicines are discovered and developed. The Company’s internal programs are focused on discovery and development of next generation drugs to treat Alzheimer’s, cancer and diabetes.
“VistaGen is a dynamic company marked by visionary technology, a rich history of innovation and a remarkable ability to navigate through intense economic and political headwinds without veering off course,” said Shawn Singh. “We believe better human response information can lead to better medicine. By using our Clinical Trials in a Test TubeTM platform to focus on how new drugs work in the body and how they interact with people with specific genetic differences, we are confident that our founding vision can become a medical reality.” He added, “I am honored to have the opportunity to lead a team so passionately focused on commercializing science that will make a difference.”
“I have worked with Shawn for eight years, and I strongly support both his appointment as CEO and my new role as President and Chief Scientific Officer,” said Dr. Ralph Snodgrass. “Together, these changes significantly broaden and strengthen our management team, enabling us to accomplish more than ever before, both commercially and scientifically, and I look forward to this new phase in our corporate development.”
“VistaGen is moving rapidly on many business fronts,” said Jon Saxe, VistaGen’s Chairman. “We are fortunate to have available someone of Shawn’s leadership skills and extensive experience with a wide range of life science companies and technologies to lead VistaGen’s efforts to realize the full commercial potential of its stem cell technologies. At the same time, the continued service of our founder, Ralph Snodgrass, as President and CSO is invaluable. Shawn’s availability as CEO on a full- time basis will enable Ralph to devote more time to strategic vision and scientific development of the platform, including collaborations with commercial partners and our esteemed network of academic stem cell research centers.”
VistaGen’s stem cell-based Clinical Trials in a Test TubeTM platform is focused on creating in human cells a comprehensive picture of the intricate details of human biology and human disease in ways that conventional animal models and non-human cell culture systems can only approximate. This enables drug developers to test for drug toxicity and efficacy in the lab quickly and efficiently, before costly human clinical trials.
Mr. Singh began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster. He later served as Chief Business Officer of SciClone Pharmaceuticals (NASDAQ: SCLN), Chief Business Officer and General Counsel of Cato Research Ltd., a global contract research and development organization, Chief Operating Officer and Managing Principal of Cato BioVentures, the venture capital affiliate of Cato Research Ltd, President of Echo Therapeutics (OTCBB: ECTE), Chairman of the Board and President of Durham Pharmaceuticals, President of Artemis Neuroscience, and Chief Executive Officer of Hemodynamic Therapeutics.
Mr. Singh received a B.A. from the University of California, Berkeley, and a J.D. from The University of Maryland School of Law. He currently serves on the Board of Directors of Echo Therapeutics and Hemodynamic Therapeutics and as a strategic advisor to Cato BioVentures and several other private biopharmaceutical companies.
VistaGen Therapeutics, Inc. is a South San Francisco-based biotechnology company that focuses on providing clinically relevant, commercially scalable, human stem cell biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. VistaGen’s Clinical Trials in a Test TubeTM platform is designed to generate predictive information that results in reduced probability of clinical trial drug failures, especially failures associated with heart and liver toxicity. VistaGen expects its new-generation stem cell-based human systems biology platform to enhance dramatically the pharmaceutical industry’s ability to deliver innovative drugs for some of the world’s most challenging diseases and conditions. For more information, visit: www.vistagen.com
?Media Contact
Christine Thomas
Russell Communications Group
(310) 922-5897
christinethomas@ruscom.com
VSTA-Using mature human heart cells produced from pluripotent stem cells, They have leveraged their Human Clinical Trials in a TestTube™ platform to develop CardioSafe 3D™, a three-dimensional (3D) bioassay system for predicting the invivo cardiac effects of new drug candidates before they are tested in humans. VSTA plans to leverage CardioSafe 3D™ to build a pipeline of new, safer, drug rescue variants of promising drug candidates that have been “put on the shelf” by pharmaceutical companies because of toxicity concerns, despite positive efficacy data signaling their potential therapeutic and commercial benefits.
VSTA-Using mature human heart cells produced from pluripotent stem cells, They have leveraged their Human Clinical Trials in a TestTube™ platform to develop CardioSafe 3D™, a three-dimensional (3D) bioassay system for predicting the invivo cardiac effects of new drug candidates before they are tested in humans. VSTA plans to leverage CardioSafe 3D™ to build a pipeline of new, safer, drug rescue variants of promising drug candidates that have been “put on the shelf” by pharmaceutical companies because of toxicity concerns, despite positive efficacy data signaling their potential therapeutic and commercial benefits.
VSTA’s Our Human Clinical Trials in a Test Tube™ platform is based upon a combination of proprietary and exclusively licensed stem cell technologies, including technologies developed over the last 20 years by renowned Canadian scientist, Dr. Gordon Keller, and Dr. Ralph Snodgrass, our founder, President and Chief Scientific Officer
VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories, after substantial investment in discovery and development, due to heart or liver toxicity or metabolism issues. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.
VSTA
http://ih.advfn.com/p.php?pid=nmona&article=57102175&symbol=VSTA
$VSTA Headlines
http://finance.yahoo.com/q/h?s=VSTA+Headlines
Wednesday April 10 2013
$VSTA Announces $36 Million Strategic Financing Agreement - Yahoo! Finance http://finance.yahoo.com/news/vistagen-announces-36-million-strategic-124737277.html
Wednesday, March 13, 2013
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an O
EDGAR Online (Wed, Mar 13)
http://biz.yahoo.com/e/130313/vsta8-k.html
Tuesday, March 12, 2013
VistaGen Therapeutics to Present Enhancements and Expanded Validation of LiverSafe 3D(TM) at Society of Toxicology's 52nd Annual Meeting
Marketwire (Tue, Mar 12)
http://finance.yahoo.com/news/vistagen-therapeutics-present-enhancements-expanded-150517204.html
Monday, March 11, 2013
VistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting
Marketwire (Mon, Mar 11)
http://finance.yahoo.com/news/vistagen-therapeutics-present-cardiosafe-3d-140000662.html
Wednesday, March 6, 2013
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S
EDGAR Online (Wed, Mar 6)
http://biz.yahoo.com/e/130306/vsta8-k.html
Monday, March 4, 2013
VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D(TM)
Marketwire (Mon, Mar 4)
http://finance.yahoo.com/news/vistagen-therapeutics-enters-strategic-collaboration-140000133.html
Thursday, February 28, 2013
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina
EDGAR Online (Thu, Feb 28)
http://biz.yahoo.com/e/130228/vsta8-k.html
Thursday, February 21, 2013
VISTAGEN THERAPEUTICS, INC. Financials
EDGAR Online Financials (Thu, Feb 21)
http://finance.yahoo.com/q/is?s=vsta
Thursday, February 14, 2013
VISTAGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
EDGAR Online (Thu, Feb 14)
http://biz.yahoo.com/e/130214/vsta10-q.html
Thursday, February 7, 2013
VistaGen's Collaborators Identify Definitive Precursor for Adult Blood and the Immune System
Marketwire (Thu, Feb 7)
http://finance.yahoo.com/news/vistagens-collaborators-identify-definitive-precursor-150633334.html
Wednesday, January 23, 2013
Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101Marketwire (Wed, Jan 23)
http://finance.yahoo.com/news/vistagen-therapeutics-successfully-completes-final-133000505.html
$VSTA LiverSafe 3D™
In collaboration with Dr. Gordon Keller, one of the world’s leading stem cell researchers, we are developing engineered cell lines and enhancing protocols to control the differentiation of pluripotent stem cells into normal, mature, human liver cells for use in a novel liver cell-based bioassay system for predicting liver toxicity and metabolism issues in connection with our drug rescue activities. We refer to this novel human liver cell-based bioassay system as LiverSafe 3D™. We plan to complete development of LiverSafe 3D in early-2013.
VISTAGEN THERAPEUTICS ON CANADAS LARGEST NEWS BROADCASTER
Technology
Our Human Clinical Trials in a Test Tube™ platform is based upon a combination of proprietary and exclusively licensed stem cell technologies, including technologies developed over the last 20 years by our co-founders, renowned Canadian stem cell scientist, Dr. Gordon Keller, and Dr. Ralph Snodgrass, our President and Chief Scientific Officer.
The proprietary and licensed technologies underlying our Human Clinical Trials in a Test Tube™ platform enable controlled differentiation of pluripotent stem cells into mature human cells specific to our predictive toxicology, drug metabolism, drug rescue and cell therapy programs.
We have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy.
We believe our stem cell technology platform, Human Clinical Trials in a Test Tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
A major challenge in the current drug development process is that conventional animal and in vitro cell culture testing can, at best, only approximate human biology.
VistaGen’s versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential toxicity of promising new drug candidates long before they are ever tested on humans. Our human pluripotent stem cell-based bioassay systems more closely approximate human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development
VSTA VistaGen is a recipient of the “Novel Reprogrammed Cells for Differentiation into Cardiomyocytes” grant funded by The National Heart, Lung, and Blood Institute (“NHLBI”). The goal of this grant is to explore novel approaches of creating patient-specific iPS cells. NHLBI’s Symposium on Cardiovascular Regenerative Medicine brings together experts in stem cell biology and clinical cardiovascular medicine to discuss research progress in the field. Through a discussion of emerging science in the field and its clinical applications, the symposium’s goal is to foster the translation of stem cell biology and research into human clinical applications. The Institute is part of the National Institutes of Health of the US Department of Health and Human Services.
$VSTA AV-101, also known as “L-4-chlorokynurenine” and “4-Cl-KYN”, is a novel prodrug candidate that we are developing for the treatment of neuropathic pain. We are also considering AV-101 Phase 2 development opportunities relating to epilepsy, Parkinson’s disease and depression.
AV-101 is a novel, orally available prodrug that is converted in the brain into an active metabolite, 7-chlorokynurenic acid (7-Cl-KYNA), which is an antagonist of the N-methyl-D-aspartate (NMDA) receptors. 7-Cl-KYNA is a synthetic analogue of kynurenic acid, a naturally occurring CNS regulatory compound, and is one of the most potent and selective blockers of the regulatory GlyB-site of the NMDA receptor.
In pre-clinical studies, AV-101 has demonstrated very good levels of oral bioavailability, rapid and efficient transport across the blood-brain barrier and preferential conversion into 7-CKYNA at the site of seizures and potential neural damage in the brain and spinal cord.
AV-101 is completing Phase 1 development in the U.S. under an active Investigational New Drug (IND) application on file at the U.S. FDA that defines the initial clinical development for neuropathic pain.
We believe the safety studies completed in our AV-101 Phase 1 clinical program may also enable Phase 2 development of AV-101 for epilepsy, Parkinson’s disease and depression.
$VSTA Contact Info
384 Oyster Point Boulevard No. 8
South San Francisco, CA 94080
Website: http://www.vistagen.com
Phone: 650-244-9990
Great find !!!
VISTAGEN THERAPEUTICS ON CANADAS LARGEST NEWS BROADCASTER
Impersonating a S.E.C. employee is a Federal criminal offence, BGMO lawyers and the S.E.C. are well aware of this con artist and his co-conspirators charades.
Anyone else who would like to report this con artist Terry Thompson to the S.E.C. for violations of the Federal criminal laws, follow the link below
Also Global Arena was not a company in the year 2000 to 2005, this con artist should be reported to the S.E.C. by all shareholders.
http://www.linkedin.com/profile/view?id=231384327&authType=name&authToken=Aole&goback=%2Ewvp_*1_*1_*1&trk=wvmx_p
http://www.sec.gov/news/press/2009/2009-39.htm
http://law.onecle.com/michigan/750-michigan-penal-code/mcl-750-217c.html
BGMO is as real as a heart attack
Just Keeping Them Honest
Gordon Keller, Ph.D.
Chairman, Director, McEwen Centre for Regenerative Medicine, University Health Network
Dr. Keller, recently named a “Top 25 Transformational Canadian” for his stem cell research, co-founded VistaGen with Dr. Ralph Snodgrass and serves as Chairman of our Scientific Advisory Board. Dr. Keller is the Director of UHN’s McEwen Centre, and Professor, Department of Medical Biophysics, University of Toronto, Ontario. He is a world leader in the field of hematopoietic development with more than 100 publications relating to blood development and stem cells. Previously, he held an endowed Chair at the Carl C. Icahn Institute for Gene Therapy and Molecular Medicine, MSSM, was a Member of the NJH, Denver, Colorado, Associate Professor, Department of Immunology, University Health Sciences Center, Denver, Colorado, a Member, Basel Institute for Immunology, Basel, Switzerland, and a Visiting Scientist at the Research Institute of Molecular Pathology, Vienna, Austria. Dr. Keller has served on several NIH study sections and is invited throughout the world to talk about his research on stem cells and blood development. Dr. Keller and Dr. Snodgrass are long-time collaborators who helped pioneer the use of stem cell systems for understanding hematopoietic development and cell biology, and as better biological systems for pharmaceutical discovery, drug rescue and drug development.
http://www.vistagen.com/?page_id=95
Stale dated numbers
TODAY`S FACT
Under the terms of the agreement, Bergamo's European subsidiary will invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen Common Stock at a price of $0.50 per share.
B/S based on this deal, VSTA has 92,421,787 O/S so BGMO would have about 1.5 times as many shares O/S ( not 20 times !!!)
At closing, the shares issued in connection with the strategic financing will represent a majority of the issued and outstanding shares of VistaGen's Common Stock.
Impersonating a S.E.C. employee is a Federal criminal offence, BGMO lawyers and the S.E.C. are well aware of this con artist and his co-conspirators charades.
Anyone else who would like to report this con artist Terry Thompson to the S.E.C. for violations of the Federal criminal laws, follow the link below
Also Global Arena was not a company in the year 2000 to 2005, this con artist should be reported to the S.E.C. by all shareholders.
http://www.linkedin.com/profile/view?id=231384327&authType=name&authToken=Aole&goback=%2Ewvp_*1_*1_*1&trk=wvmx_p
http://www.sec.gov/news/press/2009/2009-39.htm
http://law.onecle.com/michigan/750-michigan-penal-code/mcl-750-217c.html
BGMO is as real as a heart attack
Just Keeping Them Honest
Congratulations to all the shareholders, that didn't listen to the B/S on the internet and held onto their stock
Great job Mr. Herzog and Mr. Parekh, and thank you for not quitting on the shareholders
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
YOUR OPINIONS ARE WRONG AGAIN
So far the shareholders have only heard opinions please provide links to back up your opinion that this time is no different.
There is plenty of evidence that this is very different ( including a Bank Statement filed with OTC markets, and a CPA letter verifying the Bank Statement )
How BGMO Secured USD 1,000,000,000.00 CASH FUNDING
1. HSBC Bank Statement posted on OTC MARKETS Filings on Jan 29th, 2013.
2. HSBC BANK A/C Holder’s Name.
3. HSBC BANK A/C Number.
4. HSBC BANK A/C Authorized Signatory.
5. HSBC BANK A/C Bank Officer Name and Title
6. HSBC BANK A/C Bank Officer Bank E-Mail Address.
7. HSBC BANK A/C 2nd BANK OFFICER Title and E-Mail Address
8. HSBC BANK A/C Main Branch Phone Number.
CPA ADMITS IN THE 1ST Line of his Letter JAN 25TH, 2013).
“QUOTE BY CPA” I am writing this letter at your request to (“VARIFY”) certain
Information CPA received during his meeting on Jan 23rd, 2013 with the management of Bergamo Acquisition Corp.
“QUOTE BY CPA” This letter can serve as a summary of the documents only as
“ADDITIONAL” information included in the originals agreements.
“QUOTE BY CPA” BGMO AFFILIATE WAS GRANTED USD 1,000,000,000.00
National Wealth Ltd.
“QUOTE BY CPA” NATIONAL WEALTH LTD was granted USD 1,000,000,000.00
On Jan 18, 2013. For a period of three years.
“QUOTE BY CPA” The Documents reference CASH deposit with HSBC totaling
USD 1,000,000,000.00.
“QUOTE BY CPA” Pursuant to the documents through a bond power, Deed of Assignment,
Bond Power hereby referred to as “Grantee” is National Wealth Ltd, Affiliate of Bergamo Acquisition Corp.
a) CPA Letter Dated Sep 19th, 2012
b) CPA Letter Dated Jan 25th, 2013
c) OTCMARKETS Filings Section, Review Bank Statement
d) OTCMARKETS Filings Section, Review powers authorized to the
“Grantee” which is National Wealth Ltd affiliate of Bergamo Acquisition Corp
e) Bank Statement is posted showing CASH deposit of USD 1,000,000,000.00.
f) Press Release Issued on Jan 10th, 2013 and Press Release Dated Jan 31st, 2013.
HSBC USD 1,000,000,000,00 ( DONE DEAL )
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
YOUR OPINIONS ARE WRONG AGAIN
So far the shareholders have only heard opinions please provide links to back up your opinion that this time is no different.
There is plenty of evidence that this is very different ( including a Bank Statement filed with OTC markets, and a CPA letter verifying the Bank Statement )
How BGMO Secured USD 1,000,000,000.00 CASH FUNDING
1. HSBC Bank Statement posted on OTCMARKETS Filings on Jan 29th, 2013.
2. HSBC BANK A/C Holder’s Name.
3. HSBC BANK A/C Number.
4. HSBC BANK A/C Authorized Signatory.
5. HSBC BANK A/C Bank Officer Name and Title
6. HSBC BANK A/C Bank Officer Bank E-Mail Address.
7. HSBC BANK A/C 2nd BANK OFFICER Title and E-Mail Address
8. HSBC BANK A/C Main Branch Phone Number.
CPA ADMITS IN THE 1ST Line of his Letter JAN 25TH, 2013).
“QUOTE BY CPA” I am writing this letter at your request to (“VARIFY”) certain
Information CPA received during his meeting on Jan 23rd, 2013 with the management of Bergamo Acquisition Corp.
“QUOTE BY CPA” This letter can serve as a summary of the documents only as
“ADDITIONAL” information included in the originals agreements.
“QUOTE BY CPA” BGMO AFFILIATE WAS GRANTED USD 1,000,000,000.00
National Wealth Ltd.
“QUOTE BY CPA” NATIONAL WEALTH LTD was granted USD 1,000,000,000.00
On Jan 18, 2013. For a period of three years.
“QUOTE BY CPA” The Documents reference CASH deposit with HSBC totaling
USD 1,000,000,000.00.
“QUOTE BY CPA” Pursuant to the documents through a bond power, Deed of Assignment,
Bond Power hereby referred to as “Grantee” is National Wealth Ltd, Affiliate of Bergamo Acquisition Corp.
a) CPA Letter Dated Sep 19th, 2012
b) CPA Letter Dated Jan 25th, 2013
c) OTCMARKETS Filings Section, Review Bank Statement
d) OTCMARKETS Filings Section, Review powers authorized to the
“Grantee” which is National Wealth Ltd affiliate of Bergamo Acquisition Corp
e) Bank Statement is posted showing CASH deposit of USD 1,000,000,000.00.
f) Press Release Issued on Jan 10th, 2013 and Press Release Dated Jan 31st, 2013.
HSBC USD 1,000,000,000,00 ( DONE DEAL )
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
Only BGMO management knows when the buy back will start and the market will tell us before the company does. IMO
I do agree the pps need to go up, but telling the rest of the world would not be logical way of accomplishing that. BGMO needs to buy the stock back first, then tell the rest of the world.
Terry Thompson is the CON MAN but that is not his real name. that's the name this SUM BAG uses to sign up to websites
And everything this disgruntled past business associates,says should be taken with the proverbial grain of salt
Just Keeping Them Honest
BGMO is as real as a heart attack !!!!
YOU'RE WRONG AGAIN, HEARD IT ALL BEFORE ( YAWN )
HSBC USD 1,000,000,000,00 ( DONE DEAL )
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings